Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

DiabetologiaJun 8, 2026
Genetics of MASLD: a diabetes perspective

Clinical Context

We think this might be relevant to the clinical guidance for MSI/MMR Interpretation.

Alzheimers & DementiaJun 7, 2026
Age‐related increase in plasma p‐tau217 in amyloid‐beta–negative cognitively unimpaired individuals affects diagnostic interpretation

Clinical Context

We think this might be relevant to the clinical guidance for MSI/MMR Interpretation.

DiabetologiaJun 6, 2026
SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden

Clinical Context

We think this might be relevant to the clinical guidance for MSI/MMR Interpretation.

MSI/MMR Interpretation

MSI / MMRTesting Interpretation Framework

Laboratory Findings

Clinical pearl

IHC (for MMR proteins) and PCR/NGS (for MSI) are complementary. A deficiency in any of the four MMR proteins (MLH1, MSH2, MSH6, PMS2) typically defines dMMR.

Biomarker Status

pMMR / MSS

Clinical Strategy

Proficient MMR / Microsatellite Stable. Low likelihood of high response to PD-1 monotherapy in most solid tumors.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Universal testing is now recommended for all newly diagnosed colorectal and endometrial cancers.
Testing in all advanced/metastatic solid tumors to evaluate eligibility for agnostic immunotherapy.
Triggering genetic counseling for suspected Lynch Syndrome.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the TNM 8th (Colorectal) or the FIGO 2023 (Endometrial) to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

TNM 8th
FIGO 2023
HPV/p16 Oropharynx
TNM 9th Ed
SINS Score
IMWG Myeloma Frailty
IGCCCG Risk
iRECIST
IPSS-M
mrTRG
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.